T-cell prolymphocytic leukemia: update and focus on alemtuzumab (Campath-1H).

摘要: T-cell prolymphocytic leukemia (T-PLL) is a rare mature lymphoproliferative disorder. While the etiology of T-PLL unknown, recent progress in unraveling molecular basis leukemogenesis has been substantial and may yield novel therapeutic targets. distinct disease entity diagnosis can be readily made based on characteristic clinical features laboratory findings. Prior to appearance pentostatin alemtuzumab protocols, outcome for patients was exceedingly poor with median survival measured months. use particular improved remissions, remains incurable. Future collaborative efforts investigating treatment approaches will crucial improving this disease.